2020 Cancer Diagnostic Testing: A Market on the Verge of Explosion--US, Europe, Japan--Supplier Shares and Market Segment Forecasts by Test--Technological Breakthroughs, Emerging Tests, Competitive Analysis

This new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Worldwide Market Overview

- Five-year test volume and sales projections by country.

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers by country.

- Estimated universe of laboratories performing cancer diagnostic testing by country.

- Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product
suppliers by individual test and country.

- Five-year test volume and sales forecasts
for major tumor markers by country and market segment, including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers
used for cancer testing, including their operating characteristics,
features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods,
biochips/microarrays, biosensors, monoclonal antibodies, immunoassays,
chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies
and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Kyowa Medex
- Leica Biosystems
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- Roche
- Scienion
- Sequenom
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
- Vermillion
- Wako Pure Chemicals


I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes

23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin

- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Instrumentation Review And Market Needs
D. Current and Emerging Technologies
1. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
c. Sequencing
d. Microarrays/Biochips
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification

d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
VIII. France
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares

IX. Germany
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares
X. Italy
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares
XI. Japan
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares
XII. Spain
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares
XIII. U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares

XIV. U.S.A.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers Sales
And Market Shares
XV. Competitive Profiles
- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako
XVI. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technology and Applications

2020 Denmark Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Supplier Shares and Strategies, Volume and Sales Forecasts, Emerging Technologies, Instrumentation and Opportunities

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities during the next five years, and assist industry executives in developing effective

USD 2450 View Report

2020 Czech Republic Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Supplier Shares and Strategies, Volume and Sales Forecasts, Emerging Technologies, Instrumentation and Opportunities

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities during the next five years, and assist industry executives in developing effective

USD 2450 View Report

2020 Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares by Test, Country Volume and Sales Forecasts, Profiles of Leading Competitors, Emerging Tumor Markers, Technology Assessment, Instrumentation Review

This new report provides analysis of the global cancer diagnostics market, including emerging tests, Technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers. The report presents:Estimated

USD 7500 View Report

2020 US Cancer Diagnostics Market: Supplier Shares by Test, Competitive Strategies, Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation

It's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US

USD 4850 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available